Recent advances in the therapeutic strategies of glioblastoma multiforme

AF Aldoghachi, AF Aldoghachi, K Breyne, KH Ling… - Neuroscience, 2022 - Elsevier
Glioblastoma multiforme (GBM) is one of the most common, most formidable, and deadliest
malignant types of primary astrocytoma with a poor prognosis. At present, the standard of …

[HTML][HTML] Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma

B Zhao, J Wu, H Li, Y Wang, Y Wang, H Xing… - Cell Communication and …, 2023 - Springer
Glioblastoma (GBM) is the most malignant CNS tumor with a highest incidence rate, and
most patients would undergo a recurrence. Recurrent GBM (rGBM) shows an increasing …

[HTML][HTML] Glioblastoma multiforme

T Kanderi, V Gupta - StatPearls [Internet], 2022 - ncbi.nlm.nih.gov
Glioblastoma Multiforme - StatPearls - NCBI Bookshelf US flag An official website of the United
States government Here's how you know NIH NLM Logo Access keys NCBI Homepage …

[HTML][HTML] Spatial distribution of immune cells in primary and recurrent glioblastoma: a small case study

D Loussouarn, L Oliver, C Salaud, E Samarut… - Cancers, 2023 - mdpi.com
Simple Summary Glioblastoma (GBM) are the main primary brain tumors in adults. The role
of the immune system in the progression of GBM is still largely under-evaluated. Here, we …

[HTML][HTML] Challenges and Promise for Glioblastoma Treatment through Extracellular Vesicle Inquiry

GL Liguori - Cells, 2024 - mdpi.com
Glioblastoma (GB) is a rare but extremely aggressive brain tumor that significantly impacts
patient outcomes, affecting both duration and quality of life. The protocol established by …

Boron neutron capture therapy and add-on bevacizumab in patients with recurrent malignant glioma

M Furuse, S Kawabata, M Wanibuchi… - Japanese Journal of …, 2022 - academic.oup.com
Background Although boron neutron capture therapy has shown excellent survival data,
previous studies have shown an increase in radiation necrosis against recurrent malignant …

A sequential targeting strategy interrupts AKT-driven subclone-mediated progression in glioblastoma

S Kebir, V Ullrich, P Berger, C Dobersalske… - Clinical Cancer …, 2023 - AACR
Purpose: Therapy resistance and fatal disease progression in glioblastoma are thought to
result from the dynamics of intra-tumor heterogeneity. This study aimed at identifying and …

[HTML][HTML] Management of recurrent glioblastomas: what can we learn from the French glioblastoma biobank?

A Clavreul, L Autier, JM Lemée, P Augereau, G Soulard… - Cancers, 2022 - mdpi.com
Simple Summary There is no broad consensus concerning the management of recurrent
glioblastoma (rGB). Within the French GB biobank (FGB), systemic treatment is the principal …

miR-342-3p Suppresses glioblastoma development via targeting CDK6

J Yao, Y Dai, Z Liu, W Hu, Y Wan - Acta Biochimica Polonica, 2022 - abp.ptbioch.edu.pl
Background: Glioblastoma is the most malignant primary brain tumor with dysregulated
microRNAs affecting development and malignant transformation. Methods: Gene Expression …

Ganciclovir as a potential treatment for glioma: a systematic review and meta-analysis

CT Chang, HH Chen, CC Chuang, SH Chang… - Journal of Neuro …, 2023 - Springer
Background Glioma is a challenging malignant tumor with a low survival rate and no
effective treatment. Recently, ganciclovir, an antiviral drug, combined with gene therapy and …